Onyx' potential blockbuster for multiple myeloma Kyprolis wins early US FDA approval
This article was originally published in Scrip
Multiple myeloma patients who may have run out of hope have a new treatment option that may add months to their lives now that the US FDA has granted accelerated approval to Onyx Pharmaceuticals' intravenous product Kyprolis (carfilzomib), which could become a blockbuster drug.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.